As of early morning, it is the top-performing sector of the day. As a result, Seeking Alpha outlined the top 10 listed Consumer Discretionary stocks with a market cap of at least $10B in ...

Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

For LVS (NYSE:LVS), we notice a put option sweep that happens to be bullish, expiring in 10 day(s) on January 24, 2025. This event was a transfer of 467 contract(s) at a $51.00 strike. This ...

These bullet-by-bullet explanations have been constructed using the accompanying table. - Call Contracts: The right to buy shares as indicated in the contract. - Put Contracts: The right to sell ...

instead, the all-electric i4, introduced just a few years ago, makes the list in sixth place. Read up on the 10 most reliable models below and consider what you might want out of your next car.

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Consumer Reports ranks car reliability based on surveys of its over 6 million members about their own vehicles. 8 out of the 10 vehicles ranked most reliable are manufactured by Toyota.

The 23-year-old company has been on an upward trajectory, with its market cap doubling from the end of 2022 to its current $10 billion. Intra-Cellular made noise last week when its share price ...

Shares in Intra-Cellular have risen about 40 per cent over the last 12 months, giving the company a market value of roughly US$10 billion. Intra-Cellular develops ... on the offence after spinning off ...

Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 ...

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will ...

which affects about 10 times as many people as have schizophrenia and a little more than three times as many as have bipolar depression. Partly based on that prospect of an expanded market, ...